nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP1A2—Carmustine—lymphatic system cancer	0.169	0.552	CbGbCtD
Dexmedetomidine—CYP2E1—Mitoxantrone—lymphatic system cancer	0.137	0.448	CbGbCtD
Dexmedetomidine—Speech disorder—Carmustine—lymphatic system cancer	0.0054	0.00778	CcSEcCtD
Dexmedetomidine—Myocardial ischaemia—Mitoxantrone—lymphatic system cancer	0.00537	0.00774	CcSEcCtD
Dexmedetomidine—Gamma-glutamyltransferase increased—Mitoxantrone—lymphatic system cancer	0.00525	0.00756	CcSEcCtD
Dexmedetomidine—Wheezing—Bleomycin—lymphatic system cancer	0.00517	0.00744	CcSEcCtD
Dexmedetomidine—Bronchospasm—Teniposide—lymphatic system cancer	0.0051	0.00734	CcSEcCtD
Dexmedetomidine—Leukocytosis—Carmustine—lymphatic system cancer	0.00494	0.00712	CcSEcCtD
Dexmedetomidine—Hypocalcaemia—Mitoxantrone—lymphatic system cancer	0.00472	0.0068	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.00453	0.00652	CcSEcCtD
Dexmedetomidine—Nephropathy—Methotrexate—lymphatic system cancer	0.00452	0.00651	CcSEcCtD
Dexmedetomidine—Respiratory failure—Vincristine—lymphatic system cancer	0.00451	0.0065	CcSEcCtD
Dexmedetomidine—Sweating increased—Fludarabine—lymphatic system cancer	0.00443	0.00639	CcSEcCtD
Dexmedetomidine—Hyperkalaemia—Mitoxantrone—lymphatic system cancer	0.00424	0.00611	CcSEcCtD
Dexmedetomidine—Haemoglobin—Teniposide—lymphatic system cancer	0.00417	0.006	CcSEcCtD
Dexmedetomidine—Haemorrhage—Teniposide—lymphatic system cancer	0.00415	0.00597	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00411	0.00592	CcSEcCtD
Dexmedetomidine—Pneumonia—Fludarabine—lymphatic system cancer	0.00408	0.00588	CcSEcCtD
Dexmedetomidine—Blood urea increased—Mitoxantrone—lymphatic system cancer	0.00408	0.00587	CcSEcCtD
Dexmedetomidine—Abnormal vision—Carmustine—lymphatic system cancer	0.00405	0.00584	CcSEcCtD
Dexmedetomidine—Sepsis—Carmustine—lymphatic system cancer	0.00403	0.00581	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.004	0.00577	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Fludarabine—lymphatic system cancer	0.00398	0.00573	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00398	0.00573	CcSEcCtD
Dexmedetomidine—Infection—Mechlorethamine—lymphatic system cancer	0.00397	0.00572	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00395	0.00569	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00391	0.00564	CcSEcCtD
Dexmedetomidine—Sepsis—Mitoxantrone—lymphatic system cancer	0.00375	0.0054	CcSEcCtD
Dexmedetomidine—Chills—Teniposide—lymphatic system cancer	0.00372	0.00536	CcSEcCtD
Dexmedetomidine—Arrhythmia—Teniposide—lymphatic system cancer	0.0037	0.00534	CcSEcCtD
Dexmedetomidine—Haemoglobin—Fludarabine—lymphatic system cancer	0.00366	0.00528	CcSEcCtD
Dexmedetomidine—Haemorrhage—Fludarabine—lymphatic system cancer	0.00364	0.00525	CcSEcCtD
Dexmedetomidine—Visual impairment—Fludarabine—lymphatic system cancer	0.00351	0.00506	CcSEcCtD
Dexmedetomidine—Renal failure acute—Mitoxantrone—lymphatic system cancer	0.00339	0.00489	CcSEcCtD
Dexmedetomidine—Hypoxia—Methotrexate—lymphatic system cancer	0.00339	0.00488	CcSEcCtD
Dexmedetomidine—Anaemia—Teniposide—lymphatic system cancer	0.00334	0.00481	CcSEcCtD
Dexmedetomidine—Agitation—Teniposide—lymphatic system cancer	0.00332	0.00478	CcSEcCtD
Dexmedetomidine—Bronchospasm—Bleomycin—lymphatic system cancer	0.00328	0.00473	CcSEcCtD
Dexmedetomidine—Chills—Fludarabine—lymphatic system cancer	0.00327	0.00471	CcSEcCtD
Dexmedetomidine—Arrhythmia—Fludarabine—lymphatic system cancer	0.00326	0.00469	CcSEcCtD
Dexmedetomidine—Malnutrition—Fludarabine—lymphatic system cancer	0.00317	0.00457	CcSEcCtD
Dexmedetomidine—Hypertension—Teniposide—lymphatic system cancer	0.00312	0.00449	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Carmustine—lymphatic system cancer	0.00307	0.00442	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Vincristine—lymphatic system cancer	0.00306	0.00441	CcSEcCtD
Dexmedetomidine—Pneumonia—Bleomycin—lymphatic system cancer	0.00299	0.00431	CcSEcCtD
Dexmedetomidine—Confusional state—Teniposide—lymphatic system cancer	0.00297	0.00428	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00293	0.00423	CcSEcCtD
Dexmedetomidine—Anaemia—Fludarabine—lymphatic system cancer	0.00293	0.00422	CcSEcCtD
Dexmedetomidine—Infection—Teniposide—lymphatic system cancer	0.00293	0.00422	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00292	0.0042	CcSEcCtD
Dexmedetomidine—Agitation—Fludarabine—lymphatic system cancer	0.00292	0.0042	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.0029	0.00418	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00288	0.00416	CcSEcCtD
Dexmedetomidine—Tachycardia—Teniposide—lymphatic system cancer	0.00288	0.00414	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00285	0.00411	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00285	0.0041	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00282	0.00407	CcSEcCtD
Dexmedetomidine—Pleural effusion—Methotrexate—lymphatic system cancer	0.00281	0.00405	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00276	0.00398	CcSEcCtD
Dexmedetomidine—Hypotension—Teniposide—lymphatic system cancer	0.00275	0.00397	CcSEcCtD
Dexmedetomidine—Convulsion—Fludarabine—lymphatic system cancer	0.00275	0.00396	CcSEcCtD
Dexmedetomidine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00273	0.00394	CcSEcCtD
Dexmedetomidine—Haemoglobin—Bleomycin—lymphatic system cancer	0.00269	0.00387	CcSEcCtD
Dexmedetomidine—Haemorrhage—Bleomycin—lymphatic system cancer	0.00267	0.00385	CcSEcCtD
Dexmedetomidine—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00264	0.0038	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00263	0.00379	CcSEcCtD
Dexmedetomidine—Dyspnoea—Teniposide—lymphatic system cancer	0.00263	0.00378	CcSEcCtD
Dexmedetomidine—Pneumonia—Carmustine—lymphatic system cancer	0.00261	0.00376	CcSEcCtD
Dexmedetomidine—Confusional state—Fludarabine—lymphatic system cancer	0.00261	0.00376	CcSEcCtD
Dexmedetomidine—Infection—Fludarabine—lymphatic system cancer	0.00257	0.00371	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00255	0.00367	CcSEcCtD
Dexmedetomidine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00254	0.00366	CcSEcCtD
Dexmedetomidine—Apnoea—Methotrexate—lymphatic system cancer	0.00254	0.00366	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00253	0.00365	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Carmustine—lymphatic system cancer	0.00253	0.00364	CcSEcCtD
Dexmedetomidine—Rash—Mechlorethamine—lymphatic system cancer	0.00252	0.00363	CcSEcCtD
Dexmedetomidine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00252	0.00363	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.0025	0.00361	CcSEcCtD
Dexmedetomidine—Speech disorder—Methotrexate—lymphatic system cancer	0.0025	0.0036	CcSEcCtD
Dexmedetomidine—Pneumonia—Vincristine—lymphatic system cancer	0.00249	0.00359	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00244	0.00352	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00244	0.00352	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Vincristine—lymphatic system cancer	0.00243	0.0035	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00243	0.0035	CcSEcCtD
Dexmedetomidine—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00243	0.0035	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00243	0.0035	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00241	0.00347	CcSEcCtD
Dexmedetomidine—Chills—Bleomycin—lymphatic system cancer	0.0024	0.00345	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00238	0.00343	CcSEcCtD
Dexmedetomidine—Nausea—Mechlorethamine—lymphatic system cancer	0.00237	0.00342	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00237	0.00341	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.00237	0.00341	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00235	0.00338	CcSEcCtD
Dexmedetomidine—Haemoglobin—Carmustine—lymphatic system cancer	0.00234	0.00338	CcSEcCtD
Dexmedetomidine—Oliguria—Methotrexate—lymphatic system cancer	0.00233	0.00336	CcSEcCtD
Dexmedetomidine—Haemorrhage—Carmustine—lymphatic system cancer	0.00233	0.00336	CcSEcCtD
Dexmedetomidine—Abdominal pain—Teniposide—lymphatic system cancer	0.00233	0.00336	CcSEcCtD
Dexmedetomidine—Body temperature increased—Teniposide—lymphatic system cancer	0.00233	0.00336	CcSEcCtD
Dexmedetomidine—Hallucination—Carmustine—lymphatic system cancer	0.00232	0.00334	CcSEcCtD
Dexmedetomidine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00231	0.00333	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Carmustine—lymphatic system cancer	0.0023	0.00331	CcSEcCtD
Dexmedetomidine—Visual impairment—Carmustine—lymphatic system cancer	0.00225	0.00324	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00224	0.00322	CcSEcCtD
Dexmedetomidine—Hallucination—Vincristine—lymphatic system cancer	0.00222	0.00319	CcSEcCtD
Dexmedetomidine—Pain—Fludarabine—lymphatic system cancer	0.00221	0.00319	CcSEcCtD
Dexmedetomidine—Constipation—Fludarabine—lymphatic system cancer	0.00221	0.00319	CcSEcCtD
Dexmedetomidine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00221	0.00318	CcSEcCtD
Dexmedetomidine—Respiratory failure—Methotrexate—lymphatic system cancer	0.00219	0.00316	CcSEcCtD
Dexmedetomidine—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00218	0.00314	CcSEcCtD
Dexmedetomidine—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00217	0.00312	CcSEcCtD
Dexmedetomidine—Anaemia—Bleomycin—lymphatic system cancer	0.00215	0.0031	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00213	0.00307	CcSEcCtD
Dexmedetomidine—Arrhythmia—Carmustine—lymphatic system cancer	0.00208	0.003	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00207	0.00298	CcSEcCtD
Dexmedetomidine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00205	0.00295	CcSEcCtD
Dexmedetomidine—Mental disorder—Carmustine—lymphatic system cancer	0.00204	0.00294	CcSEcCtD
Dexmedetomidine—Malnutrition—Carmustine—lymphatic system cancer	0.00203	0.00293	CcSEcCtD
Dexmedetomidine—Angiopathy—Vincristine—lymphatic system cancer	0.00202	0.00291	CcSEcCtD
Dexmedetomidine—Diarrhoea—Teniposide—lymphatic system cancer	0.00202	0.0029	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00201	0.00289	CcSEcCtD
Dexmedetomidine—Mental disorder—Vincristine—lymphatic system cancer	0.00195	0.00281	CcSEcCtD
Dexmedetomidine—Chills—Mitoxantrone—lymphatic system cancer	0.00195	0.0028	CcSEcCtD
Dexmedetomidine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00194	0.00279	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00191	0.00276	CcSEcCtD
Dexmedetomidine—Confusional state—Bleomycin—lymphatic system cancer	0.00191	0.00276	CcSEcCtD
Dexmedetomidine—Infection—Bleomycin—lymphatic system cancer	0.00189	0.00272	CcSEcCtD
Dexmedetomidine—Anaemia—Carmustine—lymphatic system cancer	0.00188	0.0027	CcSEcCtD
Dexmedetomidine—Vomiting—Teniposide—lymphatic system cancer	0.00187	0.0027	CcSEcCtD
Dexmedetomidine—Sepsis—Methotrexate—lymphatic system cancer	0.00187	0.00269	CcSEcCtD
Dexmedetomidine—Agitation—Carmustine—lymphatic system cancer	0.00187	0.00269	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00186	0.00268	CcSEcCtD
Dexmedetomidine—Rash—Teniposide—lymphatic system cancer	0.00186	0.00268	CcSEcCtD
Dexmedetomidine—Dermatitis—Teniposide—lymphatic system cancer	0.00186	0.00267	CcSEcCtD
Dexmedetomidine—Headache—Teniposide—lymphatic system cancer	0.00185	0.00266	CcSEcCtD
Dexmedetomidine—Anaemia—Vincristine—lymphatic system cancer	0.00179	0.00258	CcSEcCtD
Dexmedetomidine—Agitation—Vincristine—lymphatic system cancer	0.00178	0.00257	CcSEcCtD
Dexmedetomidine—Hypotension—Bleomycin—lymphatic system cancer	0.00177	0.00256	CcSEcCtD
Dexmedetomidine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00177	0.00255	CcSEcCtD
Dexmedetomidine—Convulsion—Carmustine—lymphatic system cancer	0.00176	0.00253	CcSEcCtD
Dexmedetomidine—Hypertension—Carmustine—lymphatic system cancer	0.00175	0.00253	CcSEcCtD
Dexmedetomidine—Nausea—Teniposide—lymphatic system cancer	0.00175	0.00252	CcSEcCtD
Dexmedetomidine—Anaemia—Mitoxantrone—lymphatic system cancer	0.00174	0.00251	CcSEcCtD
Dexmedetomidine—Anxiety—Carmustine—lymphatic system cancer	0.00172	0.00248	CcSEcCtD
Dexmedetomidine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00169	0.00244	CcSEcCtD
Dexmedetomidine—Renal failure acute—Methotrexate—lymphatic system cancer	0.00169	0.00244	CcSEcCtD
Dexmedetomidine—Convulsion—Vincristine—lymphatic system cancer	0.00168	0.00242	CcSEcCtD
Dexmedetomidine—Hypertension—Vincristine—lymphatic system cancer	0.00167	0.00241	CcSEcCtD
Dexmedetomidine—Confusional state—Carmustine—lymphatic system cancer	0.00167	0.00241	CcSEcCtD
Dexmedetomidine—Infection—Carmustine—lymphatic system cancer	0.00165	0.00237	CcSEcCtD
Dexmedetomidine—Vomiting—Fludarabine—lymphatic system cancer	0.00165	0.00237	CcSEcCtD
Dexmedetomidine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00164	0.00236	CcSEcCtD
Dexmedetomidine—Rash—Fludarabine—lymphatic system cancer	0.00163	0.00235	CcSEcCtD
Dexmedetomidine—Dermatitis—Fludarabine—lymphatic system cancer	0.00163	0.00235	CcSEcCtD
Dexmedetomidine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00163	0.00235	CcSEcCtD
Dexmedetomidine—Pain—Bleomycin—lymphatic system cancer	0.00162	0.00234	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00162	0.00234	CcSEcCtD
Dexmedetomidine—Headache—Fludarabine—lymphatic system cancer	0.00162	0.00234	CcSEcCtD
Dexmedetomidine—Tachycardia—Carmustine—lymphatic system cancer	0.00162	0.00233	CcSEcCtD
Dexmedetomidine—Anxiety—Mitoxantrone—lymphatic system cancer	0.0016	0.00231	CcSEcCtD
Dexmedetomidine—Infection—Vincristine—lymphatic system cancer	0.00157	0.00226	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00156	0.00225	CcSEcCtD
Dexmedetomidine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00155	0.00224	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00155	0.00223	CcSEcCtD
Dexmedetomidine—Hypotension—Carmustine—lymphatic system cancer	0.00155	0.00223	CcSEcCtD
Dexmedetomidine—Nausea—Fludarabine—lymphatic system cancer	0.00154	0.00222	CcSEcCtD
Dexmedetomidine—Infection—Mitoxantrone—lymphatic system cancer	0.00153	0.0022	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00153	0.0022	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00151	0.00217	CcSEcCtD
Dexmedetomidine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.0015	0.00217	CcSEcCtD
Dexmedetomidine—Body temperature increased—Bleomycin—lymphatic system cancer	0.0015	0.00216	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00149	0.00215	CcSEcCtD
Dexmedetomidine—Hypotension—Vincristine—lymphatic system cancer	0.00148	0.00213	CcSEcCtD
Dexmedetomidine—Dyspnoea—Carmustine—lymphatic system cancer	0.00148	0.00213	CcSEcCtD
Dexmedetomidine—Somnolence—Carmustine—lymphatic system cancer	0.00147	0.00212	CcSEcCtD
Dexmedetomidine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00144	0.00207	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00143	0.00206	CcSEcCtD
Dexmedetomidine—Pain—Carmustine—lymphatic system cancer	0.00142	0.00204	CcSEcCtD
Dexmedetomidine—Constipation—Carmustine—lymphatic system cancer	0.00142	0.00204	CcSEcCtD
Dexmedetomidine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00137	0.00198	CcSEcCtD
Dexmedetomidine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00137	0.00197	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00137	0.00197	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00137	0.00197	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00135	0.00195	CcSEcCtD
Dexmedetomidine—Pain—Vincristine—lymphatic system cancer	0.00135	0.00195	CcSEcCtD
Dexmedetomidine—Constipation—Vincristine—lymphatic system cancer	0.00135	0.00195	CcSEcCtD
Dexmedetomidine—Pain—Mitoxantrone—lymphatic system cancer	0.00132	0.0019	CcSEcCtD
Dexmedetomidine—Constipation—Mitoxantrone—lymphatic system cancer	0.00132	0.0019	CcSEcCtD
Dexmedetomidine—Body temperature increased—Carmustine—lymphatic system cancer	0.00131	0.00189	CcSEcCtD
Dexmedetomidine—Abdominal pain—Carmustine—lymphatic system cancer	0.00131	0.00189	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00129	0.00186	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00127	0.00183	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00126	0.00181	CcSEcCtD
Dexmedetomidine—Abdominal pain—Vincristine—lymphatic system cancer	0.00125	0.0018	CcSEcCtD
Dexmedetomidine—Body temperature increased—Vincristine—lymphatic system cancer	0.00125	0.0018	CcSEcCtD
Dexmedetomidine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00122	0.00175	CcSEcCtD
Dexmedetomidine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00122	0.00175	CcSEcCtD
Dexmedetomidine—Pneumonia—Methotrexate—lymphatic system cancer	0.00121	0.00174	CcSEcCtD
Dexmedetomidine—Vomiting—Bleomycin—lymphatic system cancer	0.00121	0.00174	CcSEcCtD
Dexmedetomidine—Rash—Bleomycin—lymphatic system cancer	0.0012	0.00172	CcSEcCtD
Dexmedetomidine—Dermatitis—Bleomycin—lymphatic system cancer	0.0012	0.00172	CcSEcCtD
Dexmedetomidine—Diarrhoea—Carmustine—lymphatic system cancer	0.00113	0.00163	CcSEcCtD
Dexmedetomidine—Nausea—Bleomycin—lymphatic system cancer	0.00113	0.00162	CcSEcCtD
Dexmedetomidine—Dizziness—Carmustine—lymphatic system cancer	0.0011	0.00158	CcSEcCtD
Dexmedetomidine—Haemoglobin—Methotrexate—lymphatic system cancer	0.00109	0.00156	CcSEcCtD
Dexmedetomidine—Diarrhoea—Vincristine—lymphatic system cancer	0.00108	0.00156	CcSEcCtD
Dexmedetomidine—Haemorrhage—Methotrexate—lymphatic system cancer	0.00108	0.00156	CcSEcCtD
Dexmedetomidine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00105	0.00152	CcSEcCtD
Dexmedetomidine—Vomiting—Carmustine—lymphatic system cancer	0.00105	0.00152	CcSEcCtD
Dexmedetomidine—Dizziness—Vincristine—lymphatic system cancer	0.00105	0.00151	CcSEcCtD
Dexmedetomidine—Rash—Carmustine—lymphatic system cancer	0.00104	0.00151	CcSEcCtD
Dexmedetomidine—Dermatitis—Carmustine—lymphatic system cancer	0.00104	0.0015	CcSEcCtD
Dexmedetomidine—Visual impairment—Methotrexate—lymphatic system cancer	0.00104	0.0015	CcSEcCtD
Dexmedetomidine—Headache—Carmustine—lymphatic system cancer	0.00104	0.0015	CcSEcCtD
Dexmedetomidine—Vomiting—Vincristine—lymphatic system cancer	0.00101	0.00145	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.001	0.00144	CcSEcCtD
Dexmedetomidine—Rash—Vincristine—lymphatic system cancer	0.000997	0.00144	CcSEcCtD
Dexmedetomidine—Dermatitis—Vincristine—lymphatic system cancer	0.000996	0.00144	CcSEcCtD
Dexmedetomidine—Headache—Vincristine—lymphatic system cancer	0.000991	0.00143	CcSEcCtD
Dexmedetomidine—Nausea—Carmustine—lymphatic system cancer	0.000984	0.00142	CcSEcCtD
Dexmedetomidine—Angiopathy—Methotrexate—lymphatic system cancer	0.00098	0.00141	CcSEcCtD
Dexmedetomidine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000979	0.00141	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000974	0.0014	CcSEcCtD
Dexmedetomidine—Rash—Mitoxantrone—lymphatic system cancer	0.000971	0.0014	CcSEcCtD
Dexmedetomidine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00097	0.0014	CcSEcCtD
Dexmedetomidine—Chills—Methotrexate—lymphatic system cancer	0.000969	0.0014	CcSEcCtD
Dexmedetomidine—Headache—Mitoxantrone—lymphatic system cancer	0.000965	0.00139	CcSEcCtD
Dexmedetomidine—Mental disorder—Methotrexate—lymphatic system cancer	0.000946	0.00136	CcSEcCtD
Dexmedetomidine—Malnutrition—Methotrexate—lymphatic system cancer	0.00094	0.00135	CcSEcCtD
Dexmedetomidine—Nausea—Vincristine—lymphatic system cancer	0.00094	0.00135	CcSEcCtD
Dexmedetomidine—Nausea—Mitoxantrone—lymphatic system cancer	0.000915	0.00132	CcSEcCtD
Dexmedetomidine—Anaemia—Methotrexate—lymphatic system cancer	0.000869	0.00125	CcSEcCtD
Dexmedetomidine—Convulsion—Methotrexate—lymphatic system cancer	0.000815	0.00117	CcSEcCtD
Dexmedetomidine—Confusional state—Methotrexate—lymphatic system cancer	0.000774	0.00111	CcSEcCtD
Dexmedetomidine—Infection—Methotrexate—lymphatic system cancer	0.000762	0.0011	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000751	0.00108	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000742	0.00107	CcSEcCtD
Dexmedetomidine—Hypotension—Methotrexate—lymphatic system cancer	0.000717	0.00103	CcSEcCtD
Dexmedetomidine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000684	0.000986	CcSEcCtD
Dexmedetomidine—Somnolence—Methotrexate—lymphatic system cancer	0.000682	0.000983	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000663	0.000955	CcSEcCtD
Dexmedetomidine—Pain—Methotrexate—lymphatic system cancer	0.000656	0.000946	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000632	0.000911	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000628	0.000904	CcSEcCtD
Dexmedetomidine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000607	0.000874	CcSEcCtD
Dexmedetomidine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000607	0.000874	CcSEcCtD
Dexmedetomidine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000525	0.000757	CcSEcCtD
Dexmedetomidine—Dizziness—Methotrexate—lymphatic system cancer	0.000508	0.000731	CcSEcCtD
Dexmedetomidine—Vomiting—Methotrexate—lymphatic system cancer	0.000488	0.000703	CcSEcCtD
Dexmedetomidine—Rash—Methotrexate—lymphatic system cancer	0.000484	0.000697	CcSEcCtD
Dexmedetomidine—Dermatitis—Methotrexate—lymphatic system cancer	0.000483	0.000697	CcSEcCtD
Dexmedetomidine—Headache—Methotrexate—lymphatic system cancer	0.000481	0.000693	CcSEcCtD
Dexmedetomidine—Nausea—Methotrexate—lymphatic system cancer	0.000456	0.000657	CcSEcCtD
